Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.

Juan Ignacio RojasAgustín PappollaLiliana PatruccoEdgardo CristianoJimena MiguezSusana LiwackiVerónica TkachukMaría E BalbuenaCarlos VrechNorma DeriJorge CorrealeMariano MarrodanMaría C YsrraelitMarcela FiolFelisa LeguizamonGeraldine LueticMaría L MenichiniPablo A LopezJuan Pablo PettinicchiJuan CrinitiAlejandro CarideDarío TavoliniCarolina MainellaGisela ZangaMarcos BurgosJavier HrybAndrés BarbozaLuciana LazaroRicardo AlonsoBerenice SilvaNora Fernández LiguoriDébora NadurAníbal ChercoffAlejandra MartinezJudith SteinbergOrlando GarceaAdriana CarráMarina Alonso SerenaEdgar Carnero Contentti

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)

No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
multiple sclerosis
peritoneal dialysis
prognostic factors
type diabetes
cross sectional
machine learning
metabolic syndrome
big data
adipose tissue
patient reported
weight loss
artificial intelligence
data analysis